Answers are grounded in this paper and cite their sources.
OS Therapies is advancing a next-generation antibody-drug conjugate (ADC) technology platform, known as tunable ADCs (tADCs), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the company’s proprietary silicone linker technology, enabling the delivery of multiple payloads per linker.
No takes yet. Share an insight, caveat, or question.
Peter Hofland (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: